AqVida celebrates successful CPhI Madrid show

Hamburg, Germany:– Innovative German oncology generics specialist AqVida was able to use the landmark CPhI Madrid expo to share key messages about its products and activities.

AqVida hosted the German-based not-for-profit organization Krebsallianz, which supports cancer patients in developing countries with surplus products donated by pharmaceutical sponsors. AqVida has been an active Krebsallianz supporter since 2012and donated products with a market value of a few hundred-thousand Euro.

Krebsallianz shared AqVida’s stand at CPhI for a reception during the show during which it was able to spread its message to other key companies.

A video highlighting Krebsallianz’s collaboration is available now at https://youtu.be/nogz45SpzQk

Onco-generic announcements

The Hamburg-based company, which is dedicated to development, registration, manufacturing and licensing/distribution of oncology generics, used CPhI 2015 to introduce its New Generic products.

It announced that Imatinib, a generic version of Gleevec /Glivec, will receive marketing authorization in Germany as well as other European territories soon, ready to go to market next year, after patent expiry. It also announced that Sunitinib is now in advanced development, targeting to apply marketing authorisations within 2016, ready to launch in Europe after patent expiry in 2021 and to support commercial supplies into markets where no patent is applying.

Zero loss facility

There was great interest among many visitors about the company’s new “Zero Loss” facility to manufacture oncology generics and antibody drug conjugates (ADCs). The facility is a major innovation for the pharma industry, using totally robotic controlled filling processes for parenteral cytotoxics.

“CPhI 2015 was really successful for us,” commented AqVida CEO and founder Wolfgang Heinze.

“We made many new and interesting contacts and consolidated many of our established partner relationships.”

“Many of our conversations at the show were about our current product portfolio of onco-generics, but there was also great interest in our new developments like Imatinib and Sunitinib, which will both fill significant gaps in the market.”

“CPhI is a key platform in our field of oncology and we are looking forward to attending next year’s show in Barcelona, where we will again be an exhibitor,” Mr. Heinze added.

About AqVida

AqVida is a German pharmaceutical company that is fully dedicated and specialized in the development, registration, manufacturing and distribution of finished dosage forms mainly for the oncology sector. It has developed a portfolio of medicines for treating the most common types of cancer.

AqVida’s expertise in generic oncology products has made the company a leading partner in the pharmaceutical industry.

AqVida works alongside some of the leading names in the oncology sector. In co-operation with its partners, AqVida has achieved substantial development and growth with its oncology portfolio.

As a pharmaceutical company with an impressive track record, AqVida fulfills all client requirements from API sourcing through to EU market release for finished products. Teams of experts in development, regulatory affairs, patent issues and laboratory work bring skills and knowledge together to achieve optimum results for customers.

AqVida complies with all German and EU legal requirements for the pharmaceutical industry and is GMP certified by the German Health Authorities. As a European organisation, AqVida has the knowledge and resources to provide regulatory support to meet the requirements of the complex and highly regulated EU market.

About CPhI 2015

CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitors opportunities to arrange face-to-face meetings with potential international pharmaceutical partners and collaborators, as well as gain insights on latest industry trends.

Now in its 26th year, the 2015 event was a three-day event opening October 13 at IFEMA, Feria de Madrid, Spain. Last year’s even in Paris attracted almost 36,500 delegates and 2,500 exhibitor companies from more than 150 countries worldwide.

The CPhI series is staged by leading Global B2B Events Organizer and Publisher UBM Live More information at: http://www.cphi.com/europe/home